I have been monitoring this mode of hormone replacement since 2002, and most women have noted impressive changes not seen with standard treatment. The consistent theme from women with, either active or history of breast cancer, is,' I'd rather risk living a shorter life using this hormone Protocol than a longer one without it". This is their informed choice, their life, and their responsibility.

In November 2006, I will be reporting on 53 women ( 47 with oncology diagnoses : 28 breast cancer and 5 DCIS : 10 other) who started the Wiley protocol and the positive and negative issues involved. So far the adverse events are:

1) one 71 year old woman who had been on the WP for 3 years survived non-critical shower pulmonary embolisms and who insisted continuing her Wiley Protocol at a reduced dose with her anti-coagulation meds because it helped her with her debilitating arthritis, mood, engery better than other medications.

2) A 57 year old chest-wall relapse at the mastectomy site for stage IIB disease after using the hormones for 3 years. The lesion was removed, and the patient insists on continuing WP.

3) A new breast cancer (stage1B) discovered < 2 years after using the protocol in a 58 year old. This mirrored breast cancer was present at the same time her original breast cancer was diagnosed, but was detected on mammography about a year and a half later and observed radiographically until biopsy.

Even I, as a principal investigator for many clinical oncology trials producing evidence-based data, made the leap and began using the unconventional, unstudied Wiley Protocol for my own medical issues.
It was that month when I began to heal.....and began to investigate more.

Julie A. Taguchi Biography

Julie Taguchi, M.D., an oncologist, is a staff physician at Sansum Medical Clinic in Santa Barbara. She joined the team for the Wiley Protocol to clinically test their progesterone theories at Cottage Hospital in 1999.

• Sansum Clinic, 317 West Pueblo St., Santa Barbara, CA 93105

Specialty Department(s)
 

• Oncology/Hematology

Education
 

• BS Mount St. Mary's College – summa cum laude
• MD, University of Southern California
• Internship, Kaiser Foundation Hospital, Los Angeles
• Residency, Kaiser Foundation Hospital, Los Angeles
• Fellowship, Hematology, Kaiser Foundation Hospital, Los Angeles
• Fellowship, Oncology, University of Southern California

Board Certification(s)

• Hematology, American Board of Internal Medicine
• Internal Medicine, American Board of Internal Medicine
• Medical Oncology, American Board of Internal Medicine
   

 Affiliations
 

• Member, American College of Physicians - American Society of Internal Medicine
• Member, American Society of Clinical Oncology
• Member, American Society of Hematology
• Member, Santa Barbara County Medical Society
• Member, American College for the Advancement of Medicine
   

Staff physician – Department of Hematology and Bone Marrow Transplantation: City of Hope 1990-1992

Principal Investigator for Sansum’s clinical oncology research program
 

• Board of Directory, Tri-counties Blood Bank

• 1991

• 1993
   

T. S. Wiley
Medical Writer/Researcher

A Beverly Hills, California-based medical practitioner, Dr. Christian Renna said that he believes T.S Wiley has made, “one of the most important discoveries in this century” a simple molecular mechanism that up until now, everyone else has missed. Her revolutionary discovery is the fact that it’s the rhythm that matters in the accurate physiological replacement of hormones without side-effects for women in the second half of life. Wiley’s findings may have important implications across a wide range of areas, from the treatment of menopause and anti-aging to all of the other diseases of aging such as heart disease and stroke, Type II diabetes, cancer and Alzheimer’s disease.

The heart of Wiley’s endocrine research in women is based in chronobiology and circadian rhythmicity. Her work rests on the simple fact that the circadian clock in every cell of every human body measures one spin of the earth, and the planet’s constant companion, the moon, tracks 28 days 13 times in one revolution around the sun.

This light and dark cycle response on hormone receptors has evolved the 28 day menstrual cycle embedded in the physiological make-up of all women. That’s why replacing hormones for women with static one-time-a-day, same-amount-every-day, dosing has been so unsuccessfully lethal that most women get sick and some women die whether they take synthetic or bio-identical hormones in such a non-natural regimen.

After years of research, T.S. Wiley created The Wiley Protocol®, a patent pending delivery system consisting of bio-identical estradiol and progesterone in topical cream preparations dosed to mimic the natural hormones produced by a twenty year-old woman. The creams and their amounts vary throughout the 28 day cycle to mimic the hormone levels of youth. The Protocol is the only bio-identical hormone replacement therapy (BHRT) that has ever been developed under the scrutiny of a practicing oncologist.

The Wiley Protocol formulation and manner of dosing bio-identical HRT started out as a "thought experiment” when Wiley asked herself and the doctors she worked with the question - "if hormone replacement consisted of real bio-identical hormones and was dosed to mimic the ups and downs of the blood levels seen in a healthy menstrual cycle of a 20 year-old woman, would all of the symptoms and disease states of aging decline or even, disappear?"

Well, to her surprise and many others, the logic holds - it seems from mounting evidence on the Wiley Protocol, it was the rhythm that was always missing in other regimens.

Since the National Institutes of Health (NIH) stopped the Women’s Health Initiative (WHI) in 2003 because the synthetic hormones – Premarin and PremPro were deemed too dangerous, the common assumption among women using bio-identical regimens is that they are doing something “safer.” However, Wiley points out that the synthetics may have caused the harm reported, not just because they weren’t bio-identical hormone molecules, but because of the way they were statically dosed. Perhaps, bio-identicals, currently dosed in the Standard of Care mode, may, too, be in need of study and improvement for safety.

As a medical writer and researcher, T.S. Wiley is the author of “Sex, Lies & Menopause,” Harper Collins, 2005, a landmark work where a doctor, a philosopher, and a scientist prove that by postponing marriage and motherhood, women have accelerated the aging process, resulting in earlier menopause and, ultimately for thousands, earlier death. The book also examines the introduction of the birth control pill in the early 1960’s and the impact of not breast-feeding our young.

In her first book, “Lights Out: Sleep, Sugar and Survival, ” Pocket Books, 2000, Wiley points out how the discovery of electricity and the light bulb put us out of sync with nature. Before Edison, people spent summers sleeping less and eating heavily in preparation for winter because light triggers the hunger for carbohydrates. Now, with light available 24 hours a day, we can consume carbohydrates year round, and sleep less. In Wiley’s modest opinion, sleep is the best medicine.

T. S. Wiley spent eight years in private tutorial in molecular biology with Dr. Bent Formby, PH. D., and has been in clinical private tutorial in oncology with Dr. Julie Taguchi since 1998. She has also been a guest investigator at Sansum Medical Research Institute, Santa Barbara, CA. Her focus is on what she refers to as Darwinian Medicine or “environmental endocrinology” and evolutionary biology as it pertains to molecular medicine, oncology and genetics.

Professional Affiliations
A member of the New York Academy of Sciences, and the American Anthropological Association, Wiley often lectures, and has been a keynote speaker at the following venues:

• International Hormone Society, "Multi-Phasic, Cyclical Hormone Replacement Therapy with Bio-Identical E2/P4" in December 2005

• Keynote speaker, American College for Advancement in Medicine (ACAM), “Multi-Phasic, Cyclical Hormone Therapy with Bio-Identical E2/P4, Clinical Aspects” in May 2005

• Presenter, World Conference on Breast Cancer, “Natural progesterone and the evolution of breast cancer” in Kingston, Ontario, Canada, 1997.

Wiley has made numerous national radio and television appearances and since 2000 continues to present and lecture on Multi-Phasic, Rhythmic Cyclic BHRT and Hibernation and Metabolic States. Wiley’s Seminar’s on the Natural History of Endocrinology are attended by physicians from all over the world and they are awarded CME credits for her work.

Peer Reviewed Journals

• Stern R, Shuster S, Wiley TS, Formby B. Hyaluronidase can modulate expression of CD44. Exp Cell Res. 2001 May 15; 266(1):167-76.

• Formby B, Wiley TS.  Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis.  Mol Cell Biochem. 1999 Dec; 202(1-2):53-61.

• Formby B, Wiley TS.  Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53.  Ann Clin Lab Sci. 1998 Nov-Dec; 28(6):360-9.

• Formby B, Wiley TS.  Insulin modulates expression of the estrogen-induced genes Bcl-2, c-fos and LucCa-2 in MCF-7 breast tumor cells: evidence for association between breast cancer risk and Type 2 diabetes?  Diabetes, poster presentation, American Diabetes Association, June 16, 1997.

Projects

• “Protocol for the study of natural progesterone and its clinical effects on advanced metastic cancer.” with Dr. Bent Formby and Dr. Julie Taguchi 1999 (not reported)

• “Randomized, placebo controlled, double blind trial of testosterone in men with elevated age specific PSA and benign prostatic hypertrophy.” with Dr. David Laub and Dr. Julie Taguchi 1999  (as yet unpublished)

• “Natural progesterone for the treatment of multiple forms of cancer.” 1998 (U.S. patent-pending)

• "Insulin for Cosmetic Use" 1999 (U.S. patent)

• "Multi-Phasic, Rhythmic, Cyclic Dosing, The Wiley Protocol" 2004 (U.S. patent pending)

• “B.H.O.T.  Bio-identical Hormones On Trial: A Comparison of Routes of Administration and Dosing of Compounded Bio-Identical Hormone Therapy; Study Team: Julie Taguchi, MD, oncologist and clinical researcher, Sansum Clinic, Santa Barbara, California, Janith Williams, DNP, WHNP, RNP, researcher, consultant, clinician and faculty member, Assistant Professor, College of Nursing and Health Sciences, The University of Texas at Tyler, GYN/OB MD, Functional Medicine MD, Pharm. D., two biostatisticians, 10-12 primary care providers with expertise in care of peri-menopausal and menopausal women, Advisory Board with nationally recognized content experts and researchers, Study IRB approval in process, study number pending: The University of Texas at Tyler, Tyler, Texas April 2007”

• "Oral versus Transdermal (cream) Estradiol plus Estriol With Sequential Oral or Transdermal Progesterone, Transdermal Estradiol Patch with Oral Progesterone Versus A Control Arm in Peri-Menopausal Women "(IRB approved pending start date) Projected October 2008